Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Data on both C12 and C16 alkyltrimethylammonium bromide are used for prediction of the toxicokinetics of the C14 alkyltrimethylammonium bromide.
One study has examined the oral absorption, distribution and excretion of cetrimonium bromide.
One study has examined the percutaneous absorption of dodecyltrimethylammonium bromide in rats, in vivo.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
Absorption rate - dermal (%):

Additional information

From a toxicokinetic study with oral gavage administration of radioactive cetrimonium bromide to rats, an oral absorption rate of 3 - 9% (average 6%) has been estimated. Radioactivity in tissues declined rapidly and no bioccumulation in tissues could be expected.

From dermal exposure of rats to radioactive dodecyltrimethylammonium bromide, the percutaneous absorption of the applied radioactivity was 3.15% corresponding to 28.4 ug/cm2.

These figures are far below default absorption rates of 100%, and thus, the available data indicate limited dermal and oral absorption of the substance. As a pragmatic approach an oral and dermal absorption rate of 10% will (if necessary) be used for the risk characterisation for systemic toxicity.